Recursos frutícolas na Várzea e na terra firme em onze comunidades rurais do alto Solimões, Amazonas, Brasil

A região do Alto Solimões é muito rica em recursos genéticos agrícolas, especialmente frutícolas, mas estes recursos contribuem principalmente para a subsistência em lugar de ter um papel mais amplo no desenvolvimento regional. Um levantamento qualitativo preliminar das espécies frutícolas nativas e exóticas foi executado em 11 comunidades rurais (8 caboclas, 3 Ticunas) nos ecossistemas principais (várzea, terra firme). Observou-se 37 fruteiras nativas em 20 famílias e 10 fruteiras exóticas em 9 famílias; das nativas, 9 foram raras (observadas em 1 ou 2 comunidades) e 3 foram comuns (observadas em 10 ou 11 comunidades); das exóticas, 2 foram raras e as bananas foram encontradas em todas as comunidades, sendo a fruteira mais importante na subsistência e na comercialização. As comunidades com mais acesso imediato à várzea e à terra firme tiveram mais espécies (22,5±6,6 nativas e 6,5±2,2 exóticas), que comunidades com acesso apenas à terra firme (19,0±2,2 nativas e 5,3±0,5 exóticas), que por sua vez tiveram mais espécies que comunidades com acesso apenas à várzea (5±2 nativas e 1,5±0,9 exóticas).

Discriminação de raças primitivas de Pupunha (Bactris Gasipaes) na Amazônia brasileira por meio de marcadores moleculares (RAPDs)

A pupunha (Bactris gasipaes Kunth, Palmae) foi domesticada por seu fruto pelos primeiros povos da Amazônia Ocidental, possuindo um complexo de raças primitivas (landraces) parcialmente caracterizado e mapeado morfologicamente. Ao longo dos Rios Amazonas e Solimões, no Brasil, foram propostas três raças primitivas [Pará (Rio Amazonas), Solimões (baixo e médio Rio Solimões), Putumayo (alto Rio Solimões)], com indicações de que a raça Solimões poderia ser artefato de análise morfométrica. Marcadores RAPDs foram usados para avaliar a hipótese de três raças. Extraiu-se DNA de 30 plantas de cada raça mantida no BAG de Pupunha em Manaus, AM, Brasil. Na amplificação por PCR, 8 primers geraram 80 marcadores, cujas similaridades de Jaccard foram estimadas para agrupamento das plantas com UPGMA. O dendrograma conteve 2 grandes grupos que juntaram-se a uma similaridade de 0,535: o grupo da raça Pará conteve 26 plantas dessa raça, 5 da Putumayo e 1 da Solimões; o grupo do Rio Solimões conteve 29 plantas da raça Solimões, 19 da Putumayo e 1 da Pará. A estrutura do segundo grupo sugere que existe apenas uma raça ao longo do Rio Solimões, pois as plantas amostradas são misturadas em sub-grupos sem ordem aparente. A análise genética não apoia a hipótese de três raças e sugere que a raça Putumayo estende-se ao longo do Rio Solimões até Amazônia central. Será necessário juntar dados genéticos com morfológicos para avaliar esta nova hipótese com mais precisão.

Fenologia e produtividade do Jambo (Syzygium malaccensis) na Amazônia Central

O jambeiro (Syzygium malaccensis Merr. & Perry, Myrtaceae) é uma fruteira originária do sudeste da Ásia, hoje muito comum e apreciada na América do Sul e Central. O conhecimento de sua fenologia pode contribuir para o planejamento e o manejo do plantio, e a comercialização dos frutos. Num estudo realizado de janeiro de 1980 a dezembro de 1982 com árvores de cinco anos de idade, plantadas como ornamental em Manaus, AM, Brasil, constatou-se que a floração e a frutificação do jambeiro ocorreram duas vezes ao ano: em meado da estação chuvosa (março) e durante o período de estiagem (julho-agosto). Ambos eventos foram rápidos, com duração de sete a 15 dias, levando cerca de um mês entre a floração e a safra. O estímulo climático à floração não foi evidente. O jambeiro apresentou vingamento moderado (4 a 10%), como ocorre com a maioria das fruteiras da Amazônia. Um grande número de abelhas visitou as flores, sugerindo uma síndrome de polinização, em lugar de co-evolução com uma espécie ou gênero. A produtividade foi relativamente baixa, variando de 17,7 a 69.7 kg/planta, equivalente a 4 a 14 t/ha, sendo conveniente lembrar que essas árvores nunca foram adubadas.

Estudios evolutivos en especies de plantas nativas.

Se indagará principalmente acerca del rol de los procesos neutrales, como la deriva génica, de procesos selectivos, como la selección natural mediada por polinizadores y de procesos históricos (geológicos y climáticos del pasado) en la diversificación floral tanto a escala microevolutiva como macroevolutiva. La heterogeneidad ambiental que se presenta en amplios rangos geográficos puede promover la diferenciación entre poblaciones debido a las diferencias en condiciones físicas y biológicas. De esta manera, especies ampliamente distribuidas ofrecen la oportunidad de explorar la dinámica de los procesos evolutivos que tienen lugar a nivel interpoblacional (Dobzhansky 1970, Thompson 1999). El estudio comparativo entre especies hermanas permite comprender cómo la selección natural (adaptación) y la inercia filogenética (herencia ancestral) han modelado los rasgos de las especies que observamos en la actualidad (Díaz 2002, Schluter 2000, Futuyma 2005). Uno de los usos más importantes de la información filogenética es el de reconstruir la historia del cambio evolutivo en caracteres adaptativos mediante su mapeo en la filogenia y la reconstrucción del estado de estos caracteres en el ancestro. Así, la asociación entre transición de caracteres y transiciones en grupos funcionales es una evidencia directa de la hipótesis adaptativa de que los rasgos son seleccionados por grupos funcionales de polinizadores. Una aproximación filogenética puede permitir identificar la dirección y el tiempo de evolución. Todos estos aspectos señalan la necesidad de adoptar una perspectiva conceptualmente integrada (morfológica, genética, filogenética, filogeográfica y ecológica) en el estudio de la biología evolutiva de las flores. Estudiar como actúan los procesos micro- y macroevolutivos en las interacciones planta-polinizador, en una dimensión espacial y temporal, arrojará resultados importantes tanto en el campo teórico como en el de la conservación. Por una parte, permitirá poner a prueba hipótesis relevantes sobre la adaptación de caracteres, mientras que explorará los procesos evolutivos que subyacen a las tramas de las interacciones planta-polinizador; por otro lado, comprender el rol de los cambios climáticos pasados en la diversificación biológica es interesante tanto desde una aproximación evolutiva como desde la biología de la conservación (Avise 2000; Moritz et al. 2000; Petit et al. 2003; Hewitt 2004). Géneros a ser estudiados en este proyecto: 1- Anarthrophyllum (Fabaceae,15 spp), 2- Monttea (Plantaginaceae, 3 spp), 3- Caleolaria (Calceolariaceae 3 spp), 4- Centris (Apidae, 1 spp), 5- Jaborosa (Solanaceae, 23 spp). Metodología: Mapeado de las poblaciones. Elenco de polinizadores, frecuencia. Obtención y medición de caracteres fenotípicos florales. Néctar: concentración y vol. Aceites (peso); Morfometría geométrica (Zelditch et al. 2005). Éxito reproductivo (Dafni & Kevan 2003). Caracteres genéticos: extracción, amplificación y secuenciación: en Calceolaria se utilizarán 2 genes de cloroplasto trnH-psbA y trnS-trnG y genes anónimos nucleares de copia única (scnADN), para Jaborosa se utilizarán 3 genes de cloroplasto (trnH-psbA, TrnD-trnT y ndhF-rp32) y el gen nuclear GBSSI waxy. Finalmente para Centris cineraria se usaría el tRNA ILE y NADH Deshidrogenada subunidad 2. Análisis filogenéticos de parsimonia (Goloboff et al. 2000, Kitching et al. 1998, Nixon 2002, Farris et al. 1996, Sorenson 1999); Filogeografía: reconstrucción de redes por parsimonia (Clement et al. 2000; Posada et al. 2000), análisis de clados anidados (NCPA). Se usarán las claves de inferencia (Templeton 2004). Para todos estos análisis se utilizarán los siguientes programas: DnaSP, Network, Arlequin, MrBayes, Paup, ModelTest, Beast, TNT, WinClada TCS y GeoDis. Estadística multivariada: Los diferentes rasgos florales mencionados se analizarán utilizando distancias de Gower (datos cualitativos) y euclídeas (datos cuantitativos) mediante la técnica multivariada ACoP.

Interleukin-28B polymorphisms, IP-10, viral load and age predict the outcome of therapy in genotype 1 hepatitis C virus under real-life conditions

Background and Aims: IL28B polymorphisms, interferon (IFN)-gamma inducible protein-10 (IP-10) levels and the homeostasis model assessment of insulin resistance (HOMA-IR) score have been reported to predict rapid (RVR) and sustained (SVR) virological response in chronic hepatitis C (CHC), but it is not known whether these factors represent independent, clinically useful predictors. The aim of the study was to assess factors (including IL28B polymorphisms, IP-10 levels and HOMA-IR score) independently predicting response to therapy in CHC under real life conditions.Methods: Multivariate analysis of factors predicting RVR and SVR in 280 consecutive, treatment-naive CHC patients treated with pegylated IFN alpha and ribavirin in a prospective multicenter study.Results: Independent predictors of RVR were HCV RNA < 400,000 IU/ml (OR11.37; 95% CI 3.03-42.6), rs12980275 AA (vs. AG/GG) (OR 7.09; 1.97-25.56) and IP-10 (OR 0.04; 0.003-0.56) in HCV genotype 1 patients and lower baseline γ-glutamyl-transferase levels (OR = 0.02; 0.0009-0.31) in HCV genotype 3 patients. Independent predictors of SVR were rs12980275 AA (OR 9.68; 3.44-27.18), age < 40 yrs (OR = 4.79; 1.50-15.34) and HCV RNA < 400,000 IU/ml (OR 2.74; 1.03-7.27) in HCV genotype 1 patients and rs12980275 AA (OR = 6.26; 1.98-19.74) and age < 40 yrs (OR 5.37; 1.54-18.75) in the 88 HCV genotype 1 patients without a RVR. RVR was by itself predictive of SVR in HCV genotype 1 patients (32 of 33, 97%; OR 33.0; 4.06-268.32) and the only independent predictor of SVR in HCV genotype 2 (OR 9.0, 1.72-46.99; p=0.009) or 3 patients (OR 7.8, 1.43-42.67; p=0.01).Conclusions: In HCV genotype 1 patients, IL28B polymorphisms, HCV RNA load and IP-10 independently predict RVR. The combination of IL28B polymorphisms, HCV RNA level and age may yield more accurate pretreatment prediction of SVR. HOMA-IR score is not associated with viral response.

On rigid analytic uniformizations of Jacobians of Shimura curves

The main goal of this article is to give an explicit rigid analytic uniformization of the maximal toric quotient of the Jacobian of a Shimura curve over Q at a prime dividing exactly the level. This result can be viewed as complementary to the classical theorem of Cerednik and Drinfeld which provides rigid analytic uniformizations at primes dividing the discriminant. As a corollary, we offer a proof of a conjecture formulated by M. Greenberg in hispaper on Stark-Heegner points and quaternionic Shimura curves, thus making Greenberg's construction of local points on elliptic curves over Q unconditional.

European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring.

Given the increasing use of ambulatory blood pressure monitoring (ABPM) in both clinical practice and hypertension research, a group of scientists, participating in the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability, in year 2013 published a comprehensive position paper dealing with all aspects of the technique, based on the available scientific evidence for ABPM. The present work represents an updated schematic summary of the most important aspects related to the use of ABPM in daily practice, and is aimed at providing recommendations for proper use of this technique in a clinical setting by both specialists and practicing physicians. The present article details the requirements and the methodological issues to be addressed for using ABPM in clinical practice, The clinical indications for ABPM suggested by the available studies, among which white-coat phenomena, masked hypertension, and nocturnal hypertension, are outlined in detail, and the place of home measurement of blood pressure in relation to ABPM is discussed. The role of ABPM in pharmacological, epidemiological, and clinical research is also briefly mentioned. Finally, the implementation of ABPM in practice is considered in relation to the situation of different countries with regard to the reimbursement and the availability of ABPM in primary care practices, hospital clinics, and pharmacies.

EZH2 is essential for glioblastoma cancer stem cell maintenance.

Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2) occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma multiforme (GBM). Based on its ability to modulate transcription of key genes implicated in cell cycle control, DNA repair, and cell differentiation, EZH2 is believed to play a crucial role in tissue-specific stem cell maintenance and tumor development. Here, we show that targeted pharmacologic disruption of EZH2 by the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep), or its specific downregulation by short hairpin RNA (shRNA), strongly impairs GBM cancer stem cell (CSC) self-renewal in vitro and tumor-initiating capacity in vivo. Using genome-wide expression analysis of DZNep-treated GBM CSCs, we found the expression of c-myc, recently reported to be essential for GBM CSCs, to be strongly repressed upon EZH2 depletion. Specific shRNA-mediated downregulation of EZH2 in combination with chromatin immunoprecipitation experiments revealed that c-myc is a direct target of EZH2 in GBM CSCs. Taken together, our observations provide evidence that direct transcriptional regulation of c-myc by EZH2 may constitute a novel mechanism underlying GBM CSC maintenance and suggest that EZH2 may be a valuable new therapeutic target for GBM management.

Major, minor, trace element, Sm-Nd and Sr isotope compositions of mafic rocks from the earliest oceanic crust of the Alpine Tethys

Recent isotopic and biochronologic dating has demonstrated that the Gets nappe contains remnants of the oldest part of the oceanic crust of the Alpine Tethys. The ophiolites are associated with deep sea sediments, platform carbonates and continental crustal elements suggesting a transitional environment between continental and oceanic crust. Therefore, the ophiolites from the Gets nappe provide the opportunity to assess the nature of mantle source and the magma evolution during the final rifting stage of the European lithosphere. Trace clement analyses of mafic rocks can he divided into two sets: (1) P, Zr and Y contents are consistent with those of mid-ocean ridge basalts and REE patterns have a P-MORB affinity. (2) P,Zr Ti and Y contents are compatible with within-plate basalts and are characterized by REE spectra similar to that of T-MORB. Both have Nd isotopic compositions similar to those of synrift magma of the Red Sea and to the Rhine Graben. The model ages are in agreement with an LREE-enriched subcontinental mantle source derived from depleted mantle 800 to 900 Ma ago. Minor, trace element and Sm-Nd compositions suggest that these rocks are basaltic relies of an earliest stage of oceanic spreading i.e. an embryonic ocean. Comparison between REE patterns, Nd and Sr isotope compositions, isotopic and biochronologic ages from different Alpine Tethys ophiolites shows that samples with enriched LREE are from the older ophiolitic suites and are relies of the embryonic ocean floor. Later phases of ocean spreading are characterized by basalts that are depleted in LREE.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Purpose: Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma. Patients and Methods: Patients (age >= 18 to >= 70 years) were treated with cilengitide (500 mg) administered twice weekly intravenously in addition to standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was continued until disease progression or for up to 35 weeks. The primary end point was progression-free survival (PFS) at 6 months. Results: Fifty-two patients ( median age, 57 years; 62% male) were included. Six- and 12-month PFS rates were 69% (95% CI, 54% to 80%) and 33% ( 95% CI, 21% to 46%). Median PFS was 8 months ( 95% CI, 6.0 to 10.7 months). Twelve- and 24-month overall survival ( OS) rates were 68% ( 95% CI, 53% to 79%) and 35% ( 95% CI, 22% to 48%). Median OS was 16.1 months ( 95% CI, 13.1 to 23.2 months). PFS and OS were longer in patients with tumors with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months). The combination of cilengitide with temozolomide and radiotherapy was well tolerated, with no additional toxicity. No pharmacokinetic interactions between temozolomide and cilengitide were identified. Conclusion: Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation. J Clin Oncol 28:2712-2718. (C) 2010 by American Society of Clinical Oncology

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.

There is very limited data on isolated systemic relapses of primary central nervous system lymphomas (PCNSL). We retrospectively reviewed the clinical characteristics and outcome of 10 patients with isolated systemic disease among 209 patients with PCNSL mainly treated with methotrexate-based chemotherapy (CT) with or without radiation therapy (RT). Isolated systemic relapse remained rare (4.8%, 10/209 patients). Median time from initial diagnosis to relapse was 33 months (range, 3-94). Sites of relapse were mostly extranodal. Three patients presented with early extra-cerebral (EC) relapse 3, 5 and 8 months from the beginning of initial treatment, respectively, and 7 patients had later relapses (range, 17-94 months). Treatment at relapse included surgery alone, RT alone, CT with or without radiotherapy, or CT with autologous stem cell transplantation (ASCT). Median overall survival (OS) after relapse was 15.5 months (range, 5.8-24.5) compared to 4.6 months (range, 3.6-6.5) for patients with central nervous system (CNS) relapse (p = 0.35). In conclusion, isolated systemic relapses exist but are infrequent. Early EC relapse suggests the presence of systemic disease undetectable by conventional evaluation at initial diagnosis. Patient follow-up must be prolonged because systemic relapse can occur as late as 10 years after initial diagnosis. Whether EC relapses of PCNSL have a better prognosis than CNS relapses needs to be assessed in a larger cohort. Copyright © 2010 John Wiley & Sons, Ltd.

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

PURPOSE: To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. PATIENTS: AND METHODS: This was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg/d with dose escalation to 800 mg in case of no toxicity; during the trial this dose was increased to 800 mg/d with escalation to 1,000 mg/d. Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment. RESULTS: A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16% (95% CI, 8.0% to 34.0%) in GBM, 4.0% (95% CI, 0.3% to 15.0%) in OD, and 9% (95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor-A or -B were found. CONCLUSION: In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.